# China NMPA Inspection - Blue Moon (Chongqing) Co., Ltd. - December 31, 2020

Source: https://www.globalkeysolutions.net/records/china_inspection/blue-moon-chongqing-co-ltd/f72c1978-1c42-4701-a020-c8aaf0575e08/
Source feed: China

> China NMPA unannounced inspection for Blue Moon (Chongqing) Co., Ltd. published December 31, 2020. The Chongqing Municipal Drug Administration conducted unannounced inspections of fifteen cosmetic manufacturers, with reports published on December 31

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Notification of Unannounced Inspections of Cosmetic Manufacturers in 2020
- Company Name: Blue Moon (Chongqing) Co., Ltd.
- Publication Date: 2020-12-31
- Product Type: cosmetics
- Summary: The Chongqing Municipal Drug Administration conducted unannounced inspections of fifteen cosmetic manufacturers, with reports published on December 31, 2020. Companies included Blue Moon (Chongqing) Co., Ltd., Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd., Chongqing Bencao Duofen Technology Co., Ltd., Chongqing Bihaiyuan Daily Chemical Products Co., Ltd., Chongqing Chuangyuan Biotechnology Co., Ltd., Chongqing Timei Cosmetics Co., Ltd., Chongqing Dingshang Biological Products Co., Ltd., Chongqing Huanchi Technology Co., Ltd., Chongqing Lingfang Biotechnology Co., Ltd., Chongqing Rundemei Biotechnology Co., Ltd., Chongqing Shuguang Meizhuang Biotechnology Co., Ltd., Chongqing Xiaowan Biotechnology Co., Ltd., Chongqing Zhengren Medical Device Co., Ltd., Chongqing Zhibai Cosmetics Co., Ltd., and Chongqing Zhongjiaxin Biotechnology Co., Ltd. These inspections, based on the "Key Points for Cosmetic Production License Inspection," identified a range of compliance issues. Common violations encompassed deficiencies in quality management, such as incomplete records, inadequate internal audits, and improper handling of non-conforming materials. Problems in materials and products included inaccurate labeling, insufficient sample retention, and poor supplier management. Production management issues involved incomplete batch records, unvalidated disinfection methods, and inconsistencies in equipment status. Furthermore, several companies showed gaps in personnel training, inadequate facility layouts or environmental controls, and a lack of proper equipment documentation or status labeling. The Chongqing Municipal Drug Administration mandated that all cited companies rectify these issues within a defined period. Follow-up inspections are planned to ensure compliance. Each company is required to submit a written report detailing their rectification implementation and acceptance status to the Chongqing Municipal Drug Administration by March 1, 2021.

Company: https://www.globalkeysolutions.net/companies/blue-moon-chongqing-co-ltd/da32a722-ddb0-47af-847d-b25c3a8603af/